• LAST PRICE
    12.0000
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    11.0500/ 3
  • Ask / Lots
    12.5000/ 3
  • Open / Previous Close
    12.1700 / 12.0000
  • Day Range
    Low 11.9300
    High 12.2310
  • 52 Week Range
    Low 7.1500
    High 13.7700
  • Volume
    274,969
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 12.2
TimeVolumeIMTX
09:32 ET77512.17
09:36 ET21012.231
09:38 ET10012.15
09:54 ET10012.11
09:57 ET96212.08
09:59 ET10012.09
10:06 ET137412.18
10:08 ET20012.17
10:12 ET30012.17
10:17 ET40012.19
10:21 ET10012.22
10:30 ET10012.19
10:33 ET31012.211
10:44 ET10012.165
10:55 ET30012.15
10:57 ET540012.13
11:00 ET20012.12
11:02 ET10012.15
11:08 ET50012.15
11:13 ET10012.12
11:20 ET114812.115
11:24 ET80012.045
11:26 ET30012.07
11:27 ET10012.05
11:38 ET34412.05
11:40 ET67312.05
11:42 ET10012.055
11:44 ET40012.075
11:49 ET20012.05
11:54 ET158212
11:56 ET110011.985
11:58 ET50011.97
12:00 ET40011.94
12:02 ET10011.945
12:05 ET10011.93
12:07 ET20011.945
12:09 ET20011.96
12:18 ET170012.01
12:20 ET140012.06
12:23 ET40012.075
12:25 ET1033712.03
12:27 ET1050012
12:30 ET10011.995
12:32 ET10011.995
12:34 ET25211.94
12:36 ET173611.96
12:38 ET20011.96
12:39 ET10011.975
12:41 ET10011.95
12:43 ET40011.95
12:45 ET20011.95
12:50 ET10011.975
12:52 ET10012
12:54 ET1549812.025
12:56 ET610012
12:57 ET164511.99
12:59 ET30011.98
01:01 ET131012
01:03 ET1065011.98
01:06 ET20012
01:08 ET97712.03
01:14 ET30012.02
01:15 ET10012.02
01:26 ET40012.06
01:30 ET30012.08
01:32 ET50012.0965
01:33 ET256512.01
01:35 ET1311112.005
01:37 ET183411.95
01:39 ET10011.95
01:44 ET20011.965
01:46 ET70011.99
01:48 ET44211.995
01:50 ET10011.995
01:57 ET10012
02:06 ET65011.99
02:08 ET23712
02:13 ET167511.97
02:15 ET10011.96
02:27 ET90511.96
02:31 ET10011.95
02:33 ET10011.945
02:36 ET25011.95
02:38 ET30011.94
02:40 ET65011.94
02:42 ET70011.95
02:44 ET187212
02:45 ET820712.09
02:47 ET80712.115
02:49 ET10012.11
02:54 ET830012.03
02:56 ET70012.04
02:58 ET107512.04
03:00 ET150012.05
03:03 ET47912.07
03:05 ET10012.065
03:09 ET2242312.065
03:12 ET254412.09
03:14 ET42412.15
03:16 ET10012.135
03:21 ET40012.1
03:23 ET30012.11
03:25 ET50012.11
03:32 ET128712.115
03:34 ET125812.08
03:36 ET30012.07
03:38 ET13212.07
03:39 ET50012.06
03:41 ET67512.065
03:43 ET22512.06
03:45 ET68512.06
03:48 ET10012.04
03:50 ET90012.01
03:52 ET392211.995
03:54 ET220012.01
03:56 ET364612
03:57 ET828012.005
03:59 ET3661212
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesIMTX
Immatics NV
1.3B
-11.5x
---
United StatesNRIX
Nurix Therapeutics Inc
1.2B
-7.8x
---
United StatesVIR
Vir Biotechnology Inc
1.2B
-2.3x
---
United StatesSLNCF
Silence Therapeutics PLC
950.0M
-16.7x
---
United StatesARQT
Arcutis Biotherapeutics Inc
1.0B
-3.3x
---
United StatesPRTA
Prothena Corporation PLC
1.2B
-6.4x
---
As of 2024-06-26

Company Information

Immatics NV is a clinical-stage biopharmaceutical company that is based in the Netherlands. The Company is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The Company develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.

Contact Information

Headquarters
Paul Ehrlich-Strasse 15TUEBINGEN, Germany 72076
Phone
---
Fax
---

Executives

Non-Executive Chairman of the Board
Peter Chambre
Chief Executive Officer, Executive Director
Harpreet Singh
Chief Financial Officer
Arnd Christ
Chief Operating Officer
Steffen Walter
General Counsel
Edward Sturchio

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$1.3B
Revenue (TTM)
$79.9M
Shares Outstanding
103.1M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.75
EPS
$-1.05
Book Value
$2.85
P/E Ratio
-11.5x
Price/Sales (TTM)
15.7
Price/Cash Flow (TTM)
---
Operating Margin
-119.20%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.